NEWARK, N.J., July 20, 2015 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) will certainly be showcasing bryostatin as a potential treatment for Alzheimer’s Ailment at the Alzheimer’s Association Worldwide Conference(R) (AAIC) being held July 18-23, 2015, in Washington, DC.
Neurotrope Bioscience has actually an exclusive license to produce and commercialize bryostatin for cognitive disorders. Bryostatin is a potent modulator of an enzyme called healthy protein kinase C epsilon (PKCε), which has actually been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a feasible treatment of cognitive disorders. Based upon a number of BRNI pre-clinical and autopsy-validated human tissue studies, PKCε deficits have actually been implicated as a potential induce of Alzheimer’s disease. The Company is approaching the treatment of Alzheimer’s Ailment through the activation of PKCε. In animal models of Alzheimer’s disease, activation of PKCε has actually been shown to boost discovering and memory, improve brain neurotropic factors, and induce synaptogenesis. The Company expects to initiate a Phase 2b trial of bryostatin-1 in roughly 150 patients along with moderately significant to significant Alzheimer’s Ailment later this year.
The Alzheimer’s Association Worldwide Conference(R) (AAIC) is the world’s largest forum for the dementia research community. Worldwide investigators, clinicians and care providers gather annually to share the most recent study results, theories and discoveries to bring the globe closer to breakthroughs in dementia science.
About Alzheimer’s Disease
According to the Alzheimer’s Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer’s disease. Over 500,000 patients are diagnosed annually, along with nearly one-in-eight older Americans affected by the disease. Alzheimer’s Ailment is the third leading induce of death in the United States. There is no cure or efficient treatment for Alzheimer’s disease. Worldwide, Regarding 35.6 million people have actually the Ailment and, according to the globe Healthiness Organization, the number will certainly double every twenty years to 115.4 million people along with Alzheimer’s by 2050.
Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a concentrate on making a novel therapy for the treatment of moderately significant to significant Alzheimer’s disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can easily result in enhancement of existing synapses, reduces toxic amyloid generation, promotes synaptogenesis, and improves memory and learning, thus having the potential to boost cognitive function in Alzheimer’s disease. The Company plans to initiate our Phase 2b in 150 moderately significant to significant Alzheimer’s patients in Q4 2015.
Neurotrope is additionally conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Decide on Type C, two rare genetic diseases for which only symptomatic treatments are currently available. We have actually recently been granted Orphan Drug Designation for bryostatin as treatment of Fragile X Syndrome.
NTRP has actually exclusive licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer’s Ailment and Fragile X Syndrome, has actually a world-wide, exclusive license along with the Icahn School of Medicine at Mt. Sinai for Niemann-Decide on Type C and is partnered along with Stanford University to locate the next generation bryostatin – called bryologs.
About The Blanchette Rockefeller Neurosciences Institute
Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer’s patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance along with West Virginia University as well as in collaboration along with various other academic institutions.
Any statements contained in this press release, or gained throughout the Company’s presentation at this conference that do not describe historical facts could constitute forward-looking statements. These forward-looking statements contain statements concerning the proposed study and goals, the expectation for timing of results, and continued development of use of bryostatin for Alzheimer’s disease. Such forward-looking statements are subject to a number of risks and uncertainties and various other influences, several of which the Company has actually no manage over. Actual outcomes and the timing of certain events and circumstances could differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that could influence or induce actual outcomes to differ materially from expected or desired outcomes could include, free of limitation, the Company’s inability to obtain adequate financing, the considerable length of time associated along with drug development and related insufficient money flows and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand the Company’s business, considerable government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and various other factors are identified and described in a lot more detail in the Company’s filings along with the SEC, including the Company’s Annual Report on Form 10-Q for the fiscal quarter ended March 31, 2015. The Company does not undertake to update these forward-looking statements.
Please visit www.neurotropebioscience.com for further information.
For additional information, please contact:
Chief Financial Officer
SOURCE Neurotrope, Inc.